CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model

Molecular Cancer Therapeutics

Volumn 8, Issue 3, 2009, Pages 490-498

  Ma, Xinrong ^a   Norsworthy, Kelly ^a   Kundu, Namita ^a,b   Rodgers, William H ^a,b,c   Gimotty, Phyllis A ^d   Goloubeva, Olga ^a   Lipsky, Michael ^b   Li, Yanchun ^a   Holt, Dawn ^a   Fulton, Amy ^a,b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c LENOX HILL HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; CXCR3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; EXPERIMENTAL MOUSE; FEMALE; GENE SILENCING; HAZARD RATIO; KAPLAN MEIER METHOD; LUNG METASTASIS; LYMPH NODE; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; GENETICS; METABOLISM; METASTASIS; MORTALITY; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SURVIVAL; TUMOR CELL CULTURE;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CELL MOVEMENT; FEMALE; GENE SILENCING; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASM METASTASIS; PROGNOSIS; RECEPTORS, CXCR3; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 66449121642     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0485     Document Type: Article

References (26)

1. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56 (Pubitemid 32225831)
2. Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 2008;25:345-356
3. Walser TC, Rifat S, Ma X, et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastastic breast cancer. Cancer Res 2006;66:7701-7707 (Pubitemid 44289229)
4. Luster AD, Leder P. IP-10, a C-X-C chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993;178:1057-1065 (Pubitemid 23260444)
5. Goldberg-Bittman L, Sagi-Assif O, Meshel T, et al. Cellular characteristics of neuroblastoma cells: regulation by the ELR-CXC chemokine CXCL10 and expression of a CXCR3-like receptor. Cytokine 2005;29: 105-117 (Pubitemid 40029606)
6. Datta D, Flaxenburg JA, Laxmanan S, et al. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res 2006;66:9509-9518 (Pubitemid 44623649)
7. Walser TC, Ma X, Kundu N, et al. Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model. J Immunother 2007;30:490-498 (Pubitemid 46988082)
8. Kundu N, Walser TC, Ma X, et al. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother 2005;54:981-987 (Pubitemid 41187706)
9. Walser TC, Fulton AM. The role of chemokines in the biology and therapy of breast cancer. Breast Dis 2004;20:137-143 (Pubitemid 39600453)
10. Scotten CJ, Wilson JL, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002;62:5930-5938 (Pubitemid 35204756)
11. Smith MCP, Luker KE, Gargow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004;64:8604-8612 (Pubitemid 39552073)
12. Bertolini F, Dell'Agnola C, Mancuso P, et al. CXCR4 neutralization a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002;62:3106-3112 (Pubitemid 34602402)
13. Zagzag D, Kukyanov Y, Lan L, et al. Hypoxia-inducible factor 1 and VEGF up-regulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006;86:1221-1232 (Pubitemid 44789912)
14. Tamamura H, Hori A, Kanzaki N, et al. T140 analogs as CXCR4 antagonists identified as antimetastatic agents in the treatment of breast cancer. FEBS Lett 2003;550:79-83. (Pubitemid 37281361)
15. Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002;62:7328-7334 (Pubitemid 36025256)
16. Goldberg-Bittman L, Neumark E, Sagi-Assif O, et al. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol Lett 2004;92:171-178 (Pubitemid 38470065)
17. Kawada K, Sonoshita M, Sakashita H. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004;64:4010-4017 (Pubitemid 38697317)
18. Furuya M, Suyama T, Usui H, et al. Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum Pathol 2007;38:1676-1687 (Pubitemid 47589091)
19. Suyama T, Furuya M, Nishiyama M, et al. Up-regulation of the interferon γ (IFN-γ)-inducible chemokines IFN-inducible T-cell a chemoattractant and monokine induced by IFN-γ and of their receptor CXC receptor 3 in human renal cell carcinoma. Cancer 2005;103:258-267 (Pubitemid 40129284)
20. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocyte leukemia. Blood 2000;95:627-632 (Pubitemid 30041679)
21. Engl T, Relja B, Blumenberg C, et al. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 2006;78:1784-1793 (Pubitemid 43295576)
22. Kawada K, Hosogi H, Sonoshita M, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 2007;26:4679-4688 (Pubitemid 47067410)
23. Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathologic prognostic factors. J Clin Pathol 2007;60:596-599 (Pubitemid 46975211)
24. Zipin-Roitman A, Meshel T, Sagi-Assif O, et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007;67:3396-3405 (Pubitemid 46724880)
25. Klatte T, Seligson DB, Leppert JT, et al. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol 2008;179:61-66 (Pubitemid 350216740)
26. Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig and I-TAC, acts as functional receptor for platelet factor 4. J Exp Med 2003;197:1537-1549 (Pubitemid 36682550)